Article
MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
Bioorganic & medicinal chemistry letters - 1 Jun 2018
Nair Anilkumar G, Zeng Qingbei, Selyutin Oleg, Rosenblum Stuart B, Jiang Yueheng, Yang De-Yi, Keertikar Kerry, Zhou Guowei, Dwyer Michael, Kim Seong Heon, Shankar Bandarpalle, Yu Wensheng, Tong Ling, Chen Lei, Mazzola Robert, Caldwell John, Tang Haiqun, Agrawal Sony, Liu Rong, Kong Rong, Ingravallo Paul, Xia Ellen, Zhai Ying, Nomeir Amin, Asante-Appiah Ernest, Kozlowski Joseph A
Abstract excerpt
HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination regimen. Herein, we describe the discovery and characterization of silyl proline-containing HCV NS5A inhibitor MK-8325 with good pan-genotype activity and acceptable pharmacokinetic properties.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.